TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25668998
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine 0.5 μg/kg followed by epidural dexmedetomidine 0.5 μg/kg along with 5 ml; 0.25% ropivacaine
Study: 25668998
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 1 μg/kg followed by epidural fentanyl 1 μg/kg along with 5 ml; 0.25% ropivacaine
Study: 24622263
Drug: daglutril (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: daglutril (300 mg/day)
Study: 16782685
Drug: Stuttering Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stuttering Treatment Research Evaluation and Assessment Tool (STREAT)
Study: 8692115
Drug: High-dose cytosine-arabinoside/daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytosine-arabinoside/daunorubicin (HDAC)
Study: 31369152
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA with propofol and remifentanil)
Study: 25454683
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT) with home exercise
Study: 24428802
Drug: Dietary behavior
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary behavior modification treatment (1.5 hours of individual counseling at study start, 1 hour at follow-up home visits after 6 weeks, support through cell phone text messages every two weeks, aimed to reduce dietary intake by 500 kcal/day)
Study: 9166373
Drug: Emerging therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerging therapies for multiple sclerosis management, specific therapies not detailed, duration not specified.
Study: 8319063
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g of a negative oral contrast agent (oral magnetic particles) administered in 800 ml of a viscous suspension
Study: 31425479
Drug: Non-ipilimumab control
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Non-ipilimumab control treatments
Study: 30277862
Drug: rilonacept (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilonacept (320 mg loading dose at day 0, then 160 mg for 5 subsequent weekly doses)
Study: 26882015
Drug: Pafuramidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pafuramidine (100 mg orally twice a day for 10 days)
Study: 26882015
Drug: Pentamidine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentamidine (4 mg/kg intramuscularly once daily for 7 days)
Study: 24993817
Drug: Beclometasone/formoterol DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclometasone/formoterol DPI (children: 200 μg/24 μg, adolescents/adults: 400 μg/24 μg)
Study: 24993817
Drug: Beclometasone/formoterol DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclometasone/formoterol DPI (adolescents/adults: 400 μg/24 μg)
Study: 24993817
Drug: Normalization for
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normalization for BDP/formoterol dose
Study: 21737312
Drug: Individualized intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized intervention to foster optimal antiretroviral treatment-taking behavior
Study: 19568773
Drug: Aprepitant triple-therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant triple-therapy regimen (aprepitant, ondansetron, and dexamethasone)
Study: 12578455
Drug: Fluorouracil (0.5‐mg/mL)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (0.5‐mg/mL) applied to the rhinostomy site for 5 minutes during surgery
Study: 12578455
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (isotonic sodium chloride solution) applied to the rhinostomy site for 5 minutes during surgery
Study: 8639069
Drug: Subcutaneous dihydroergotamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dihydroergotamine mesylate (1 mg)
Study: 8639069
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan succinate (6 mg)
Study: 2062512
Drug: Early photocoagulation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early photocoagulation (scatter and focal treatment)
Study: 6852359
Drug: CDCA (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDCA (750 mg/day in three divided doses at meals)
Study: 22269820
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cisatracurium (0.78 ± 0.15 μg.kg(‐1).min(‐1))
Study: 22269820
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus injection of cisatracurium (1.09 ± 0.33 μg.kg(‐1).min(‐1))
Study: 22269820
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cisatracurium
Study: 22269820
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus injection of cisatracurium
Study: 20578382
Drug: Single usage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single usage of acupoints of Shaoyang meridian (Fengchi (GB 20), Yifeng (TE 17), Wangu (GB 12) at the affected side) from the 3rd day to the 14th day, followed by routine acupoints (Hegu (LI 4) on both sides, Fengchi (GB 20), Quchi (LI 11), Yangbai (GB 14) at the affected side) after the 15th day, along with oral Prednisone.
Study: 20578382
Drug: Routine acupoints
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine acupoints (same as the routine ones in the observation group) from the 3rd day, along with oral Prednisone.
Study: 8529329
Drug: Intravenous EXP3174
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous EXP3174
Study: 8529329
Drug: Oral EXP3174
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral EXP3174
Study: 6305113
Drug: Preoperative irradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative irradiation with a total dose of 25.5 Gy in fractions of 5.1 Gy daily for 5 days
Study: 27822727
Drug: Handcrafted vacuum‐assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handcrafted vacuum‐assisted therapy (changed every 72 hours)
Study: 27822727
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (debridement and cure with soap every 24 hours)
Study: 23932021
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) - 28 sessions at a partial pressure of oxygen of 240 kPa for 90 min
Study: 21748755
Drug: 5 or
Normalized name: Acys-5 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or 25 mg of lenalidomide
Study: 17606973
Drug: Ixabepilone 32
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone 32 mg/m² 3-hour infusion (arm A)
Study: 17606973
Drug: Ixabepilone 6
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone 6 mg/m² 1-hour infusion daily for 5 consecutive days (arm B)
Study: 16939989
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid add-on
Study: 10821130
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor plus amlodipine (group II, n=13)
Study: 10821130
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor alone (group I, n=17)
Study: 2004543
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 2000 mg daily for 10 days
Study: 29164599
Drug: JWH‐018 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: JWH‐018 2 mg
Study: 29164599
Drug: JWH‐018 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: JWH‐018 3 mg
Study: 26136534
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g whey protein (PRO) postexercise
Study: 23032867
Drug: S‐ICD (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐ICD (subcutaneous implantable cardioverter-defibrillator)
Study: 6688025
Drug: Atracurium 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.8 mg kg‐1
Study: 30914216
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplement use
Study: 15332578
Drug: Aspirin (250‐500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (250‐500 mg) + Clopidogrel (300 mg prehospital, then 75 mg/day after TLT)
Study: 15332578
Drug: Aspirin (250‐500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (250‐500 mg)
Study: 10691156
Drug: Universal screening
Normalized name: STATLOCK UNIVERSAL PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal screening (50-g glucose challenge test followed by 3-h 100-g OGTT if plasma glucose at 1 h was >= 7.8 mmol/l)
Study: 10691156
Drug: Risk factor-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk factor-based screening (3-h 100-g OGTT at 32 weeks if any risk factor for GDM was present)
Study: 30240907
Drug: Double contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double contrast injection in conjunctival lymphatics
Study: 29202568
Drug: Hybrid hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hybrid hyaluronic acid (two intrarticular injections)
Study: 29202568
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight hyaluronic acid (two intrarticular injections)
Study: 26518870
Drug: HOCO-DHA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOCO-DHA (50 g/day) in muffins and cookies
Study: 26518870
Drug: Barley flour
Normalized name: Barley malt flour
DrugBank: Barley malt (DB10980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barley flour (4.36 g/day of β-glucan) and control oil (50 g/day)
Study: 26518870
Drug: Barley flour
Normalized name: Barley malt flour
DrugBank: Barley malt (DB10980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barley flour (4.36 g/day of β-glucan) and HOCO-DHA (50 g/day; DHA dosage 3 g/day)
Study: 26518870
Drug: All-purpose flour
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-purpose flour and control oil (50 g/day)
Study: 19748675
Drug: VPDT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPDT + ITA (4 mg ITA injection)
Study: 19748675
Drug: VPDT alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPDT alone (sham injection)
Study: 15139789
Drug: Intravenous palonosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous palonosetron 0.25 mg
Study: 15139789
Drug: Intravenous palonosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous palonosetron 0.75 mg
Study: 15139789
Drug: Intravenous palonosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous palonosetron (0.25 or 0.75 mg)
Study: 15139789
Drug: Intravenous dolasetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dolasetron 100 mg
Study: 15139789
Drug: Intravenous dolasetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dolasetron
Study: 11489748
Drug: Low-dose 13-cis-retinoic
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose 13-cis-retinoic acid
Study: 11489748
Drug: Oral cavity
Normalized name: INVEST ANTI-NEOPLASTIC DRUGS LIP,ORAL CAVITY AND PHARYNX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cavity site
Study: 2292283
Drug: Aspirin 1.2
Normalized name: Aspirin 1.2 GM Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1.2 g single dose
Study: 2292283
Drug: Flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 50 mg t.d.s. for three days
Study: 31550958
Drug: Compound glycyrrhizin
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound glycyrrhizin combined with fractional CO2 laser and triamcinolone acetonide solution
Study: 31550958
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser and triamcinolone acetonide solution (Control)
Study: 28847206
Drug: Anacetrapib 100
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib 100 mg once daily
Study: 21332817
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg per os daily (n = 33)
Study: 19874160
Drug: Post-treatment social
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment social support
Study: 16696911
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (regular therapy)
Study: 14566102
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of prednisolone
Study: 14566102
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of prednisolone
Study: 10660503
Drug: Cefpirome 1
Normalized name: cefpirome 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome 1 g
Study: 10660503
Drug: Cefpirome 2
Normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome 2 g
Study: 6142467
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg zopiclone
Study: 2433653
Drug: Bleomycin (BLM)
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bleomycin (BLM) given perioperatively and 3 and 6 months postoperatively at a dosage of 150 mg per course (total: 450 mg)
Study: 20467011
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g twice daily) with hypocaloric diet
Study: 18192785
Drug: Valaciclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 500 mg once daily
Study: 9065105
Drug: Intravenous gamma‐globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gamma‐globulin 1 gm/kg per week
Study: 9065105
Drug: Intravenous gamma‐globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gamma‐globulin 1 gm/kg per week with dexamethasone
Study: 9065105
Drug: Salvage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage treatment with 60 mg of prednisone per day
Study: 1326165
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment with myelopid (MP)
Study: 1326165
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with myelopid (MP)
Study: 6418094
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg/day) + Nifedipine (30 mg/day)
Study: 6418094
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg/day) + Placebo (3 tablets/day)
Study: 6418094
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg/day) + Placebo (3 tablets/day) during Phase II
Study: 26577065
Drug: 10mg oral
Normalized name: OPIPZA 10mg Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg oral pure THCV administered daily for five days
Study: 26577065
Drug: 1mg intravenous
Normalized name: bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1mg intravenous THC administered on the fifth day
Study: 26577065
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered daily for five days
Study: 26577065
Drug: THCV in
Normalized name: THCV
DrugBank: Tetrahydrocannabivarin (DB11755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THCV in combination with THC
Study: 24438504
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with sorafenib (800 mg daily) and transcatheter arterial infusion (TAI) with cisplatin (65 mg/m2/cycle)
Study: 18678161
Drug: Shu-needling therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shu-needling therapy
Study: 15951542
Drug: Mesalazine enema
Normalized name: mesalamine Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine enema (1 g at bedtime)
Study: 8852905
Drug: 5-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-valent pneumococcal conjugate vaccine (PCV)
Study: 1642935
Drug: IV diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV diclofenac 2 mg kg‐1/24 h for 2 days
Study: 6377959
Drug: Oral controlled‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral controlled‐release morphine (MST 30 mg)
Study: 22243564
Drug: Aleurone-rich cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleurone-rich cereal products (27 g aleurone/d)
Study: 18581941
Drug: Albuterol (ALB,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (ALB, 16 mg x d(-1))
Study: 2244710
Drug: Albuterol (ALB)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (ALB)
Study: 7604951
Drug: Oral terfenadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terfenadine 60 mg twice daily
Study: 7604951
Drug: Oral astemizole
Normalized name: Astemizole
DrugBank: Astemizole (DB00637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral astemizole 10 mg once daily
Study: 2113796
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg orally
Study: 18441772
Drug: Dapsone gel
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone gel 5% (n=578)
Study: 18441772
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel (n=547)
Study: 14514389
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg bid for 14 days)
Study: 14514389
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment influencing prolactin or other sexual hormones)
Study: 10611136
Drug: Methoxsalen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxsalen (50 mg oral)
Study: 2524549
Drug: MSD recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSD recombinant DNA hepatitis B vaccine (2 micrograms doses, 3 doses I.M. at monthly intervals)
Study: 2524549
Drug: SKF recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF recombinant DNA hepatitis B vaccine (2 micrograms doses, 3 doses I.M. at monthly intervals)
Study: 2524549
Drug: MSD plasma-derived
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSD plasma-derived vaccine (2 micrograms doses, 3 doses I.M. at 0, 1, 2 months)
Study: 1201630
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly dose-fractionation (12 fractions in 28 days)
Study: 1201630
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly dose-fractionation (6 fractions in 18 days)
Study: 31160251
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: ipilimumab 3 mg/kg plus nivolumab 1 mg/kg, two cycles every 3 weeks
Study: 31160251
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: ipilimumab 1 mg/kg plus nivolumab 3 mg/kg, two cycles every 3 weeks
Study: 31160251
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: ipilimumab 3 mg/kg for two cycles every 3 weeks followed by nivolumab 3 mg/kg for two cycles every 2 weeks
Study: 29381993
Drug: Nefopam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (20 mg in 98 mL saline for 20 minutes after induction)
Study: 29381993
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 mL saline)
Study: 23874094
Drug: Cefuroxime 250
Normalized name: cefuroxime 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 250 mg twice daily for mild-moderate exacerbation or 500 mg twice daily for severe exacerbation for 7 days
Study: 21208909
Drug: F4 protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F4 protein (10, 30, or 90 μg/dose) adjuvanted with AS01
Study: 21208909
Drug: F4 protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F4 protein (10, 30, or 90 μg/dose) reconstituted with water for injection
Study: 19805690
Drug: Flow cytometric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow cytometric measurement of minimal residual disease (MRD) at day 15 of induction therapy
Study: 17426059
Drug: GVD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVD regimen (gemcitabine 1000 mg/m², vinorelbine 20 mg/m², pegylated liposomal doxorubicin 15 mg/m² for transplant-naive patients; gemcitabine 800 mg/m², vinorelbine 15 mg/m², pegylated liposomal doxorubicin 10 mg/m² for post-transplant patients)
Study: 15525924
Drug: IA morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA morphine with bupivacaine injected 10 minutes before tourniquet release
Study: 15525924
Drug: IA morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA morphine with bupivacaine injected after tourniquet release
Study: 17201879
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg p.o. twice daily for 3 days)
Study: 12355944
Drug: Gemcitabine or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine or its combination therapies
Study: 9718247
Drug: Nortriptyline (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (titrated to 50-150 ng/ml)